We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
...better
To paraphrase the Francesca Washtell's City Whispers article: Mark Crossley's remuneration has doubled, at the same time that legal concerns/ actions are high, the legal dept is very busy. Hinting that the unknown liability of these pending actions makes Indivior a risky casino share, and therefore Crossley's increased rewards were/are unmerited.
She could have gone further. The decision by 5 of the board - safety in numbers - to sell up a combined £5 million shares on 9th March at £15 was a terrible optic during the SP turmoil, and certainly no vote of confidence in the depressed SP at the time. PR wise - what on earth were they thinking?! Kathryn Hudson, company secretary, ridding herself of shares on almost a weekly basis, either by selling direct or transferring to her partner - another really bad look. And no director purchases of shares at what some would argue is a bargain basement price. It begs the obvious question, what do they know that we, the mere shareholders, don't?
All of the above lends itself to the narrative that Littleton1 is following/ even promoting. And I can understand that. It's clear that Indivior do not know what their potential legal liabilities are, or how some of the cases are playing out, or could. The statement that they made that provisions could be materially different from actual, is so open ended, but slanted on the negative side, that it needs a LOT more clarity in the coming quarterly reports.
However, balance is required here. Directors can buy and sell as they please and that is no indication of the state of the company if they do either, nor do they necessarily know more than the average shareholder.
Investor relations are open to all. You can phone or e mail Tim Owens or Jason Thompson (has anyone)? You can even phone or e mail Mark Crossley.
You would assume, rightly or wrongly, that the likes of Morgan Stanley, have been in touch with the above and sought re assurances about some of the current issues, and have been satisfied enough by the responses that they've been happy to increase their holdings post Feb results. That has to be a positive.
Legal actions are part and parcel of any pharmas daily life. The statement that Indivior made about not being able to quantify the liabilities was what has set the hare racing.
As Indivior forecast future earnings to year end in Feb, probably as a tactic to try to undo some of the negative headwinds about the c £250million legal provision, earnings and to a lesser degree profits are not key in the next quarterly statement - as unless they've deviated significantly from Feb's indications, they've been booked - move on.
Nor is the listing in the US a priority. We'd like to know, sure.
The priority for the main board to address on the May conference call and in its report, is the elephant in the room, legal actions, and progress or otherwise made. They can't be rolling out the "we still don't know our liabilities" line. They have to do
have a look at Mail on Sunday dated 4/4/23
Francesca Washtells
CITY WHISPERS
Well, I've held Indv for several years, with multiple purchases between £15.23 and £1.76 between Sept 2018 and last month. I'll probably add a few more when the ISA sub becomes available next week. A really decent banker, top buy in the FTSE350 the last 2 or 3 years in a row. A bargain today, and almost certainly a top riser this year yet again.
Lol only thing that changed is stock dropped. Tango Cash should take himself out of the market, since his entire investment philosophy is narrative following price.
Look through the list of outstanding action in any pharma company’s profile.
Tango Cash, You wrote the following on 13th March 2023:
D.L. - stop talking out of your rear.
Yes the sp was always going down today along with most UK stocks due to US Bank failure fallout.
In fact sp will probably be a bit up and down until April dnd when trading update and NASDAQ listing takes place.
Then it's boom time.
We still in a fall out period also following the litigation news. Things will return to normal post April IMHO.
So what has changed as you were bullish on this share?
Tango Cash. Only a month ago you were making cogent even bullish noises about Indivior, post results. Now you've turned very negative. Not a lot has changed in that period,so why the new negative sentiment from you?
Worst company I bought, massive mistake
This is a true dog of a share, sell before you get f**ked over. A total ****e case
Scroll the list of outstanding action in the annual report its clear the legal department is still busy.
Most of it is unquantified meaning at this stage there is no telling how bad the impact could be for the company.
More money in the US than UK, getting added to major indices (which means lots of passive money buying the stock), more healthcare focused investors, more sell side coverage, etc.
Also, Pfizer is a slow growth behemoth. Why should it be valued at a high PE? Not sure why that would even be the comparison.
A NASDAQ listing in the company’s main market will enhance investor relations.US investors dont necessarily want sterling exposure or have to pay UK transfer stamp for that matter.Research coverage in the US is superior to UK,especially post MIfID2.
GWPharmaceuticals delisted from AIM ,listed on Nasdaq and was acquired in 2021.Could happen here albeit litigation is ongoing.
It's dropping due to the uncertainty over the legal action. The current provision should be enough, however, it's caveated by Indivior in their that it may not be, and that's alarming for potential investors.
Once the action is resolved, and we don't know when that is but should get an update next month, we should see a recovery.
I don't buy the Nasdaq being the silver bullet for a share price recovery either. If you look at some of the other pharmas there eg Pfizer, their PE s are fairly low/ depressed - probably good value tbf.
Why is this corript dog ****e dropping every day for the last 1 month, FFS
@idkmybffjill imho the numbers appear decent and it's a shame we can't access new markets in the hope of increasing our takings. dyor etc
What a complete dog this is
Cashola, can you rephrase what you said? I don’t get it.
Not scary at all from where I'm sat. However, that map in their pdf, it's all the richer countries. If the US wasn't hellbent on conquering China & Russia, the takings could be more than doubled.
Nothing too scary on first reading
https://www.indivior.com/resources/dam/id/1147/Annual%20Report%20and%20Accounts%202022.pdf
Okay so basically have nothing concrete, besides saying the stock price is down and therefore everything about the company sucks.
DYOR and read the final results dated 16/2/23
They just finished the second buyback. Litigation is a fact of life for every pharma company.
Do you have something actually legitimate besides the stock price dropping? Price is driving your narrative.
Litigation no buybacks falling knife.
Please provide evidence based on revenue and profits that this is a sinking ship? Thanks.